ECSP21031200A - Uso de reboxetina para el tratamiento de narcolepsia - Google Patents
Uso de reboxetina para el tratamiento de narcolepsiaInfo
- Publication number
- ECSP21031200A ECSP21031200A ECSENADI202131200A ECDI202131200A ECSP21031200A EC SP21031200 A ECSP21031200 A EC SP21031200A EC SENADI202131200 A ECSENADI202131200 A EC SENADI202131200A EC DI202131200 A ECDI202131200 A EC DI202131200A EC SP21031200 A ECSP21031200 A EC SP21031200A
- Authority
- EC
- Ecuador
- Prior art keywords
- narcolepsy
- treatment
- reboxetin
- reboxetine
- cataplexy
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 3
- 229960003770 reboxetine Drugs 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La patente consiste en métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21031200A true ECSP21031200A (es) | 2021-05-31 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202131200A ECSP21031200A (es) | 2018-10-15 | 2021-04-30 | Uso de reboxetina para el tratamiento de narcolepsia |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (es) |
| JP (2) | JP2022504975A (es) |
| KR (2) | KR20240119194A (es) |
| CN (1) | CN112888430A (es) |
| AU (3) | AU2019361915A1 (es) |
| BR (1) | BR112021007019A2 (es) |
| CA (1) | CA3115983A1 (es) |
| CL (1) | CL2021000924A1 (es) |
| CO (1) | CO2021004681A2 (es) |
| CR (1) | CR20210514A (es) |
| EC (1) | ECSP21031200A (es) |
| IL (2) | IL282311B2 (es) |
| MX (2) | MX2021004207A (es) |
| PE (1) | PE20211199A1 (es) |
| SG (1) | SG11202103588WA (es) |
| WO (1) | WO2020081461A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2023068747A1 (ko) * | 2021-10-19 | 2023-04-27 | 단국대학교 천안캠퍼스 산학협력단 | 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| AU2005256944A1 (en) * | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
| KR102192554B1 (ko) * | 2013-03-13 | 2020-12-18 | 에스케이바이오팜 주식회사 | 탈력발작의 치료 |
-
2019
- 2019-10-14 CR CR20210514A patent/CR20210514A/es unknown
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/ja active Pending
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/es unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/es unknown
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/ko active Pending
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/pt unknown
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/zh active Pending
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en not_active Ceased
- 2019-10-14 IL IL282311A patent/IL282311B2/en unknown
- 2019-10-14 IL IL319177A patent/IL319177A/en unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/ko not_active Ceased
-
2021
- 2021-04-12 MX MX2025003477A patent/MX2025003477A/es unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/es unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/es unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/es unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en not_active Abandoned
-
2025
- 2025-02-23 AU AU2025201286A patent/AU2025201286A1/en active Pending
- 2025-06-10 JP JP2025096479A patent/JP2025134749A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021004681A2 (es) | 2021-06-21 |
| AU2025201286A1 (en) | 2025-03-13 |
| AU2023200917A1 (en) | 2023-03-23 |
| IL282311B2 (en) | 2025-08-01 |
| WO2020081461A1 (en) | 2020-04-23 |
| EP3866768A1 (en) | 2021-08-25 |
| PE20211199A1 (es) | 2021-07-01 |
| CR20210514A (es) | 2021-11-12 |
| MX2025003477A (es) | 2025-05-02 |
| MX2021004207A (es) | 2021-08-11 |
| AU2019361915A1 (en) | 2021-05-13 |
| JP2025134749A (ja) | 2025-09-17 |
| IL319177A (en) | 2025-04-01 |
| KR20240119194A (ko) | 2024-08-06 |
| NZ775057A (en) | 2024-09-27 |
| CL2021000924A1 (es) | 2021-09-03 |
| EP3866768A4 (en) | 2022-01-05 |
| IL282311A (en) | 2021-05-31 |
| IL282311B1 (en) | 2025-04-01 |
| KR20210071046A (ko) | 2021-06-15 |
| JP2022504975A (ja) | 2022-01-13 |
| SG11202103588WA (en) | 2021-05-28 |
| BR112021007019A2 (pt) | 2021-07-13 |
| CN112888430A (zh) | 2021-06-01 |
| CA3115983A1 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| CL2020001783A1 (es) | Composiciones que comprenden microbiota coseleccionada y métodos para su uso | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX393613B (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MX394475B (es) | Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |